DE2125427A1 - Therapeutisches Mittel - Google Patents
Therapeutisches MittelInfo
- Publication number
- DE2125427A1 DE2125427A1 DE19712125427 DE2125427A DE2125427A1 DE 2125427 A1 DE2125427 A1 DE 2125427A1 DE 19712125427 DE19712125427 DE 19712125427 DE 2125427 A DE2125427 A DE 2125427A DE 2125427 A1 DE2125427 A1 DE 2125427A1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- melatonin
- administration
- dose
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title description 7
- 229940124597 therapeutic agent Drugs 0.000 title description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 28
- 229960003987 melatonin Drugs 0.000 claims description 28
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 28
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 18
- 206010044565 Tremor Diseases 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 206010015037 epilepsy Diseases 0.000 description 7
- 230000007958 sleep Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 208000034308 Grand mal convulsion Diseases 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- VPZKNFMERCJWEN-UHFFFAOYSA-M sodium 2,4-dioxoimidazolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CC(=O)NC1=O VPZKNFMERCJWEN-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002745 epiphysis Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000033618 Elevated mood Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000006633 Tonic-Clonic Epilepsy Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- -1 heterocyclic indole compound Chemical class 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000003560 paroxystic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4039370A | 1970-05-25 | 1970-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2125427A1 true DE2125427A1 (de) | 1971-12-09 |
Family
ID=21910742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712125427 Pending DE2125427A1 (de) | 1970-05-25 | 1971-05-21 | Therapeutisches Mittel |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3642994A (enExample) |
| BE (1) | BE767566A (enExample) |
| CA (1) | CA960966A (enExample) |
| DE (1) | DE2125427A1 (enExample) |
| FR (1) | FR2100679B1 (enExample) |
| GB (1) | GB1356965A (enExample) |
| NL (1) | NL7106993A (enExample) |
| ZA (1) | ZA713249B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654361A (en) * | 1986-01-27 | 1987-03-31 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Method of lowering intraocular pressure using melatonin |
| GB8727099D0 (en) | 1987-11-19 | 1987-12-23 | Cellena Cell Eng A G | Compositions containing melantonin/homologues |
| GB2225517B (en) * | 1988-11-26 | 1993-03-31 | Motorola Inc | Telephone circuits |
| AU5787999A (en) * | 1998-08-26 | 2000-03-21 | Andrei Zakharovich Afanasiev | Method for treating neurodegenerative disorders |
| US7361681B2 (en) * | 2003-03-28 | 2008-04-22 | Sygnis Bioscience Gmbh & Co. Kg | Method of treating amytrophic lateral sclerosis using melatonin |
| WO2010062153A1 (es) * | 2008-11-27 | 2010-06-03 | GARCÍA PÉREZ, Miguel, Ángel | Composiciones farmacéuticas que contienen melatonina para tratar quemadura en tejidos y órganos internos causadas por sustancias corrosivas |
-
1970
- 1970-05-25 US US40393A patent/US3642994A/en not_active Expired - Lifetime
-
1971
- 1971-02-12 CA CA105,249A patent/CA960966A/en not_active Expired
- 1971-05-19 ZA ZA713249A patent/ZA713249B/xx unknown
- 1971-05-21 NL NL7106993A patent/NL7106993A/xx not_active Application Discontinuation
- 1971-05-21 DE DE19712125427 patent/DE2125427A1/de active Pending
- 1971-05-24 GB GB1659171A patent/GB1356965A/en not_active Expired
- 1971-05-24 FR FR7118707A patent/FR2100679B1/fr not_active Expired
- 1971-05-24 BE BE767566A patent/BE767566A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2100679B1 (enExample) | 1975-06-06 |
| US3642994A (en) | 1972-02-15 |
| NL7106993A (enExample) | 1971-11-29 |
| BE767566A (fr) | 1971-11-24 |
| GB1356965A (en) | 1974-06-19 |
| ZA713249B (en) | 1972-01-26 |
| FR2100679A1 (enExample) | 1972-03-24 |
| CA960966A (en) | 1975-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69028542T2 (de) | Felbamat zur Behandlung der Lennox-Gastaut syndrome | |
| Culebras et al. | Magnetic resonance findings in REM sleep behavior disorder | |
| DE69213814T2 (de) | Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie | |
| Hunter et al. | Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication | |
| DE69632743T2 (de) | Verfahren zur regulierung des vagaltonus | |
| DE3247062C2 (enExample) | ||
| DE69333014T2 (de) | Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks | |
| DE69201660T2 (de) | Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma. | |
| DE69123178T2 (de) | Verwendung von Uridin zur pharmakologischen Behandlung der peripheren Komplikationen bei Diabetes | |
| DE69512760T2 (de) | Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden | |
| DE69605531T2 (de) | Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans | |
| DE69635754T9 (de) | Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe | |
| EP0575613B1 (de) | Verwendung der aminosäure glycin zur herstellung von arzneimitteln mit antistress-, stressschutz- und nootroper wirkung | |
| Gilbert | Effects of smoking and nicotine on EEG lateralization as a function of personality | |
| Aschan et al. | The influence of hypnotic suggestion on vestibular nystagmus | |
| Patterson | SKIN CONDUCTANCE RESPONDING/NONRESPONDING AND PUPILLOMETRICS IN CHRONIC SCHIZOPHRENIA A CONFIRMATION OF GRUZELIER AND VENABLES | |
| DE69518438T3 (de) | Behandlung von übereregten nervenzellenfunktionen | |
| DE2125427A1 (de) | Therapeutisches Mittel | |
| Sandman | Physiological responses during escape and non-escape from stress in field independent and field dependent subjects | |
| EP0618797B1 (de) | Bilobalid enthaltende pharmazeutische zubereitungen zur behandlung von spannungs- und angstzuständen | |
| Martineau et al. | Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour | |
| EP0294538B1 (de) | Verwendung von Nigerizin zur Herstellung eines Mittels zur Behandlung von Virus-Erkrankungen | |
| DE3234061C2 (enExample) | ||
| Hung et al. | " Tarantula eyes' | |
| EP0467369A2 (de) | Verwendung von Furosemid zur Behandlung von allergischer Konjunktivitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| OHW | Rejection |